Phathom Pharmaceuticals recently announced that it has dosed the first patient in its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA tablets for eosinophilic esophagitis (EoE) in adults, with ...
pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: ...
Phathom Pharmaceuticals (NASDAQ:PHAT), a biopharmaceutical company with a market cap of approximately $956 million, announced Tuesday that it has dosed the first patient in its Phase 2 pHalcon EoE-201 ...
FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...
The MarketWatch News Department was not involved in the creation of this content. -- Over 790,000 total VOQUEZNA(R) prescriptions filled to date -- Filled VOQUEZNA prescriptions increased 28% from Q2 ...
FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...
Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback